Loading…

Auna S.A. Class AAUNACompetitor analysis, valuation and peers

United States · USD·Health Care›Medical/Nursing Services
Momentum weak 28
Mkt cap
$309M
US dollars, full cap
Free float
90%
of shares outstanding
$/day
$1.01M
20-day average traded
Fwd P/E
4.1×
forward earnings
ROIC−WACC
+2.1 pp
WACC 6.2%
Hurdle
-35 pp
Req g minus delivered
Official | Implied
B+ / B
agencies · bond market
Next earnings
118 days
16 Mar 2027
Close · USD$4.18
1D-12.4%
1W-10.9%
1M-23.0%
3M-20.4%
6M-4.6%
YTD-15.0%
1Y-16.4%
ATR %5.3%
Beta0.83
52w lowhigh33.5% off high

What Auna does

Employees: 15,254

Auna at a glance

Size Auna (AUNA) is a United States Health Care company (Medical/Nursing Services) with a market value of $309M, the 3055th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.18 on 18 Nov 2026.

Performance Over six months the shares fell 4.6%, against -3.5% for the median peer and -2.2% for the United States market (cap-weighted) — 9th lowest of 20 in its peer set.

Growth Revenue grew 16.8% over the last twelve months (peer median +5.1%); the operating margin is 12.5% (peer median 8.0%).

Valuation It trades at 4.1× forward earnings against a peer median of 17.6× (cheapest of 13).

Price implies For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +24%, so the hurdle is -35 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.1 points above its cost of capital (6.2% WACC).

Credit Auna has 1 bond outstanding ($365M), rated B+ by the agencies and trading like B at a weighted spread of 388 bp.

Short interest Short interest is 2.0% of the free float (30 Oct 2026).

Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).

Relative performance

10011012021 May 202621 Aug 202618 Nov 2026Peer median 98AUNA 95
Six months, rebased to 100: Auna against the median of its 20 peers (local-currency closes).

Auna financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.36B$1.23B$1.17B$1.04B$639M
Revenue growth—+5%+13%+62%—
Gross profit$501M$437M$434M$358M$219M
EBITDA$237M$226M$246M$207M$99.8M
Net income$4.08M$27.4M$29.4M-$67.8M-$22.3M
Free cash flow$118M$48.1M$34.6M-$26.5M-$12.1M
Capital expenditure$39.1M$40.6M$37.8M$44.1M$39.6M
Total debt$1.09B$1.10B$1.01B$1.06B$926M

Quarterly statements and history in the cockpit →

Auna competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%3218NIOXDRAGARWQ300642AYUPAM12JSLLIDXACLSRTA127120301060DNAWELLFLGTNEPHROPLUSGMRSAUNA6-month return →1-month return →
Up and to the right = strong over both horizons. Auna is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×25×50×75×3218NIOXM129860JSLLIDXSRTAWELLNEPHROPLUSGMRS1951AUNARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Auna is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%3218NIOXSTLNDRAGARWQ300642AYUPA9860JSLLACL301060WELLNEPHROPLUSGMRS1951AUNAGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Auna is the large dot.

Auna competitors and peer comparison

How Auna compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Auna against its 20 peers (data as of 18 Nov 2026)
MeasureAUNAPeer medianRank in peer set
1-month return-23.0%-6.8%3rd lowest of 21
6-month return-4.6%-3.5%9th lowest of 20
Distance from 52-week high-33.5%-26.3%9th lowest of 21
Revenue growth (TTM)+16.8%+5.1%9th highest of 21
Operating margin12.5%8.0%8th highest of 21
Forward P/E4.1×17.6×cheapest of 13
Growth the price implies (Req g, 7 yrs)-10.7%6.6%4th least demanding of 17
Growth delivered (Del g)+24.4%+15.4%5th highest of 17
Hurdle (Req g minus delivered)-35.1 pp-10.9 pp3rd least demanding of 17
ROIC minus cost of capital+2.1 pp-2.5 pp8th highest of 20
EV / EBITDA5.6×9.8×4th cheapest of 13
Net debt / EBITDA4.0×1.5×most indebted of 14
Bond spread388 bpn/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Auna AUNAUnited States$309M-5%+17%13%4.1×-10.7%+24.4%
Universal Vision Biotechnology 3218.TWOTaiwan$309M-4%+5%31%9.2×-13.8%+15.4%
NIOX NIOX.LUnited Kingdom$325M+3%+3%22%19.8×3.4%+15.3%
Oncology Institute STLNUnited States$326Mn/a+35%-3%n/a5.4%+21.8%
Dr. Agarwal'S Eye Hospital DRAGARWQ.NSIndia$292M+14%+20%21%n/a19.6%+27.5%
Tellgen 300642.SZChina$328M-11%+5%8%n/a18.8%-5.8%
Australian Unity Ltd Pref AYUPA.AXAustralia$352M+17%0%-2%n/a-14.9%+9.6%
M1 Kliniken M12.DEGermany$368M+1%-28%13%16.4×-5.3%+17.9%
ADICON 9860.HKHong Kong$393M+5%+1%4%24.6×12.3%-1.5%
Jeena Sikho Lifecare JSLL.NSIndia$394M-55%+135%32%17.4×7.3%+42.6%
Integral Diagnostics IDX.AXAustralia$413M-22%+26%9%14.7×7.8%+17.7%
Australian Clinical Labs ACL.AXAustralia$418M+68%-1%8%17.8×4.3%+2.6%
Strata Critical Medical SRTAUnited States$443M-10%+23%-4%86.3×n/an/a
JS Link 127120.KSSouth Korea$458M-62%+39%-83%n/an/an/a
Shanghai Labway Clinical Laboratory 301060.SZChina$518M-17%-19%6%n/a5.9%+3.2%
Ginkgo Bioworks DNAUnited States$547M+9%-44%-242%n/an/an/a
WELL Health Technologies WELL.TOCanada$661M-9%+29%6%10.1×10.1%+94.5%
Fulgent Genetics FLGTUnited States$702M+53%+5%-38%n/an/an/a
Nephrocare Health Services NEPHROPLUS.NSIndia$702M+1%+33%13%48.8×36.6%+31.6%
GMR Solutions GMRSUnited States$714M-8%-4%14%5.9×-19.6%-4.0%
Jinxin Fertility 1951.HKHong Kong$758M-4%+7%11%23.1×17.8%+12.4%

Auna bonds and credit

Auna has 1 bond outstanding with $365M face value. The agencies rate it B+; its bonds trade like B. Weighted yield 8.74%, a spread of 388 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Which companies are Auna's closest peers?
The cockpit's peer set: Universal Vision Biotechnology (3218.TWO), NIOX (NIOX.L), Oncology Institute (STLN), Dr. Agarwal'S Eye Hospital (DRAGARWQ.NS), Tellgen (300642.SZ), Australian Unity Ltd Pref (AYUPA.AX), M1 Kliniken (M12.DE), ADICON (9860.HK).
Is Auna expensive compared with its peers?
On forward p/e it trades at 4.1× against a peer median of 17.6×, cheapest of 13 in its peer set. For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +24%, so the hurdle is -35 pp: the price already allows for a slowdown.
How has Auna stock performed?
Over six months to 18 Nov 2026 the shares returned -4.6% against -3.5% for the median peer; over one year -16.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.